Chronic Venous Occlusions Treatment Market Report 2026

The chronic venous occlusions treatment market size has grown strongly in recent years. It will grow from $7.15 billion in 2025 to $7.6 billion in 2026 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to increasing prevalence of venous disorders, wider availability of endovascular treatment options, growth in hospital-based interventional procedures, rising awareness of chronic venous diseases, expanded use of anticoagulant therapies.

The chronic venous occlusions treatment market size is expected to see strong growth in the next few years. It will grow to $10.08 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to increasing aging population base, rising demand for outpatient venous procedures, growing focus on early disease diagnosis, expansion of advanced imaging-assisted treatments, increasing adoption of next-generation venous devices. Major trends in the forecast period include increasing adoption of minimally invasive venous interventions, rising use of advanced venous stenting technologies, growing preference for combination device and drug therapies, expansion of image-guided endovascular procedures, enhanced focus on long-term occlusion management.

The rising incidence of obesity is expected to drive the growth of the chronic venous occlusion treatment market in the coming years. Obesity is a medical condition defined by excessive body fat accumulation, generally indicated by a body mass index of 30 or higher. Treatment for chronic venous occlusion helps manage obesity-related complications such as edema and skin changes by improving venous blood flow and reducing inflammation, thereby supporting better overall management of obesity-related vascular issues. For instance, in March 2023, according to the World Heart Federation, a Switzerland-based global cardiovascular organization, approximately 2.3 billion adults and children worldwide were classified as overweight or obese, and based on current trends, the number of individuals living with obesity is projected to reach 2.7 billion by 2025. Therefore, the increasing prevalence of obesity is contributing to the growth of the chronic venous occlusion treatment market.

Major companies operating in the chronic venous occlusion treatment market are focusing on the development of innovative solutions, including implantable medical devices designed to treat symptomatic venous outflow obstruction in patients with chronic venous insufficiency. Implantable medical devices are surgically placed products intended to remain inside the body for extended periods to diagnose, monitor, or treat medical conditions. For example, in June 2024, Koninklijke Philips N.V., a Netherlands-based technology company, launched the Duo Venous Stent System, an implantable medical device for chronic venous occlusion treatment. The Duo Venous Stent System features a dual-layer design that improves flexibility and radial strength to provide optimal vein support. Its advanced coating enhances biocompatibility and reduces the risk of thrombosis, while the precise delivery system allows accurate placement in complex anatomical conditions.

In February 2025, Stryker Corporation, a US-based medical technology company, acquired Inari Medical, Inc. for an undisclosed amount. Through this acquisition, Stryker aims to enter the high-growth peripheral vascular segment, strengthen its interventional treatment portfolio, and accelerate innovation in minimally invasive vascular therapies. Inari Medical, Inc. is a US-based medical device company focused on developing mechanical thrombectomy solutions for venous thromboembolism and other vascular disorders.

Major companies operating in the chronic venous occlusions treatment market are Cardinal Health Inc., Bayer AG, Sanofi S.A., 3M Company, Bristol-Myers Squibb Company, Medtronic PLC, Becton, Dickinson and Company (BD), Stryker Corporation, Boston Scientific Corporation, Terumo Corporation, Ethicon Inc., Philips Medical Systems, Teleflex Incorporated, Cook Group Incorporated, Merit Medical Systems Inc., Integer Holdings Corporation, Penumbra Inc., Inari Medical, Argon Medical Devices Inc., AngioDynamics Inc., Rontis Corporation, Endologix, Richard Wolf GmbH, SIGVARIS AG, enVVeno Medical Corporation, LimFlow SA.

North America was the largest region in the chronic venous occlusions treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic venous occlusions treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chronic venous occlusions treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the chronic venous occlusions treatment market by increasing the cost of imported venous stents, catheters, angioplasty balloons, imaging systems, and pharmaceutical raw materials. Hospitals and specialty clinics in North America and Europe are most affected due to reliance on imported interventional devices, while Asia-Pacific faces pricing pressure on device manufacturing inputs. These tariffs are contributing to higher procedure costs and slower procurement cycles. However, they are also encouraging regional manufacturing of venous devices, localized drug production, and strategic sourcing partnerships that support long-term supply stability.

The chronic venous occlusions treatment market research report is one of a series of new reports that provides chronic venous occlusions treatment market statistics, including chronic venous occlusions treatment industry global market size, regional shares, competitors with a chronic venous occlusions treatment market share, detailed chronic venous occlusions treatment market segments, market trends and opportunities, and any further data you may need to thrive in the chronic venous occlusions treatment industry. This chronic venous occlusions treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Chronic venous occlusion is a condition involving the long-term blockage or obstruction of veins, commonly affecting the legs or arms, which disrupts normal blood flow and can result in symptoms such as swelling, pain, and skin changes. Treatment is aimed at managing symptoms, slowing disease progression, and preventing related complications.

The primary product types used in chronic venous occlusion treatment include devices and drugs. Devices are instruments, apparatuses, machines, or implants designed to prevent, diagnose, or treat medical conditions. In chronic venous occlusion management, devices help restore proper blood flow and improve overall venous health, supporting effective treatment outcomes. These products are used for various applications, including varicose veins, venous stasis ulcers, edema, deep vein thrombosis, and others, across healthcare settings such as hospitals, clinics, ambulatory surgery centers, trauma centers, and others.

The chronic venous occlusion treatment market consists of revenues earned by entities by providing services such as magnetic resonance imaging (MRI), fluoroscopy, computerized tomography (CT) scanning, anticoagulation therapy, and surgical intervention. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic venous occlusion treatment market also includes sales of anticoagulants, thrombolytic agents, pain relievers, and anti-inflammatory drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.